The Advantages of the MabPair™ Platform

Single-Drug Entity with the Power of Two Antibodies

  • Bring the synergy of simultaneously targeting two pathways
  • Allows different IgG isotypes and stoichiometry between the two antibodies, unlike bispecific antibodies
  • Reduced cost compared to combination of two separate antibodies

Can Be Applied to Different Therapeutic Areas

  • Oncology
  • Immuno-Oncology
  • Inflammation
  • Infectious diseases
  • Metabolic diseases

Novel Technology for Making Bifunctional Antibody Products

Streamlined Conventional Manufacturing Process